Evidence map›Paper›PMID 42865522›Full record

ArticleFrontiers in nephrology2026

Anti-GBM disease shortly after clinically presumed ANCA-associated vasculitis in an 85-year-old patient: a case report and literature review.

Hiroki Ito, Hiyu Abe, Yuya Suzuki, Kentaro Yano, Fumiya Sato, Takaki Numahata, Risa Ishikawa, Akari Endo-Matsumoto, Keiji Matsumoto, Tsubasa Yuki and 6 more

Abstract readCase Reports
In one paragraph

Article in Frontiers in nephrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors.

Hiroki Ito *Division of Nephrology and Hypertension, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Hiyu Abe *Division of Nephrology and Hypertension, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Yuya SuzukiDivision of Nephrology and Hypertension, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Kentaro YanoDivision of Nephrology and Hypertension, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Fumiya SatoDivision of Nephrology and Hypertension, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Takaki NumahataDivision of Nephrology and Hypertension, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Risa IshikawaDivision of Nephrology and Hypertension, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Akari Endo-MatsumotoDivision of Nephrology and Hypertension, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Keiji MatsumotoDivision of Nephrology and Hypertension, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Tsubasa YukiDivision of Nephrology and Hypertension, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Ayaka KamadaDivision of Nephrology and Hypertension, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Hideaki HashimotoDivision of Nephrology and Hypertension, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Go AnanDivision of Nephrology and Hypertension, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Katsuya IshiyamaDivision of Nephrology and Hypertension, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Takuo HiroseDivision of Nephrology and Hypertension, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan.
Takefumi MoriDivision of Nephrology and Hypertension, Faculty of Medicine, Tohoku Medical and Pharmaceutical University, Sendai, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Sequential emergence of anti-glomerular basement membrane (GBM) disease after anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) is rare. Case presentation: An 85-year-old woman presented with fever, edema, elevated myeloperoxidase (MPO)-ANCA, mild urinary abnormalities, markedly elevated urinary tubular injury markers, and negative serum anti-GBM antibodies measured by chemiluminescent enzyme immunoassay. Renal biopsy was not performed because of advanced age, severe dementia, antiplatelet therapy, and the family's preference for non-invasive management. She was clinically presumed to have AAV and achieved apparent clinical remission with prednisolone alone, although MPO-ANCA remained positive. However, 2.5 months after the initial AAV diagnosis, she developed rapidly progressive kidney failure requiring dialysis, accompanied by severe hematuria, increased proteinuria, urinary casts, and markedly elevated anti-GBM antibodies. Clinically diagnosed anti-GBM disease was treated with methylprednisolone pulse therapy, prednisolone, plasma exchange, and hemodialysis. Although renal recovery was not achieved, anti-GBM antibodies became negative, and she remained clinically stable on maintenance hemodialysis for over 4 years while receiving low-dose prednisolone. Conclusion: This case suggests that anti-GBM disease can emerge shortly after apparent clinical remission of AAV. ANCA-mediated GBM injury and age-related GBM changes may contribute to subsequent anti-GBM autoimmunity, although these mechanisms remain hypothetical in this patient. Prompt anti-GBM antibody testing should be considered when a rapid, unexplained decline in kidney function occurs during or after AAV treatment.

Indexed as

ANCA - associated vasculitisanti-glomerular basal membrane nephritisanti-glomerular basement antibody disease (anti-GBM disease)elderlyMPO- ANCA

Identifiers

PMID42865522
PMCPMC13654772

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.